Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy

Abstract

Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases

“…[18][19][20] Our results confirm the safety profile of rituximab. 11,13,14 We showed that 13 out of the 16 clinically improved patients had either an improvement or a stability of the NCS parameters. Our NCS analysis is limited by the retrospective collection of the data and the heterogeneity of the tested nerves.…”

“…However, there are currently no guidelines recommending a specific drug. 11 Rituximab, a monoclonal anti-CD20 antibody, has recently been used for the treatment of anti-myelin-associated glycoprotein (MAG) antibody polyneuropathy 12 and is currently used in chronic lymphoproliferative diseases and several autoimmune disorders. In CIDP, several small retrospective cohorts or single-case studies have reported possible efficacy.…”

Second regional plasmapheresis conference and workshop for Southeast Asia (SEA) on the immunomodulatory role of plasma exchange in central and peripheral nervous system disorders, Kuala Lumpur, Malaysia, 9th December 2017

“…Fu Liong Hiew (FLH) provided an overview of the clinical presentation and the available three evidence-based treatments for CIDP, IVIG, corticosteroids, and TPE. [28][29][30][31] He highlighted the tough decision of many clinicians in deciding first-line treatment due to combination of factors; cost, effectiveness, and side effects of treatments. Although TPE is a proven treatment for CIDP, its use is often reserved to severely disable patients not responding to other conventional first-line treatments.…”

Mycophenolate mofetil in paediatric autoimmune or immune‐mediated diseases of the central nervous system: clinical experience and recommendations

“…The rash gradually resolved over 2 weeks and she did not experience post-herpetic neuralgia. On day 2 of the illness, the white blood cell count was 6.04910 9 .…”

“…[3][4][5][6] MMF has been used for nearly two decades in myasthenia gravis, 7,8 although its role is less clear in chronic inflammatory demyelinating polyradiculoneuropathy. 9 In central nervous system (CNS) autoimmune and immune-mediated conditions, MMF has been increasingly used in relapsing demyelinating diseases such as neuromyelitis optica spectrum disorders (NMOSD) 4,10-14 and myelin oligodendrocyte glycoprotein (MOG)-associated disease. 13,15,16 Other uses in CNS disease include autoimmune/immunemediated encephalitis 17 and cerebral vasculitis, 18 while its role is still uncertain in multiple sclerosis, [19][20][21][22] and seems to be limited in opsoclonus myoclonus ataxia syndrome.…”